Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

doi:10.1182/blood-2018-05-853192

Skip Nav Destination

ERRATUM| July 26, 2018

Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

Blood (2018) 132 (4): 458–459.

https://doi.org/10.1182/blood-2018-05-853192

In Table 3 on page 2716 of the 21 December 2017 issue, the second and third column headings are reversed. The second column heading should read “SCT (n = 8),” and the third column heading should read “No SCT (n = 8).” The corrected Table 3 is shown below.

In lines 9 and 10 of the left column on page 2714, “7 patients (88%)” should read “4 patients (50%).”

In the next-to-last line of the right column on page 2715, “the majority (7 of 8)” should read “4.”

In lines 5 and 6 of the left column on page 2716, “patients who received SCT” should read “patients who did not receive SCT.”

The errors have been corrected in the online version of the article.

2018

Table 3.

Characterization of CR patients in remission at end of study (n = 16) by transplant status

Characteristics	CR patients in remission at EOS (n = 16)		All other CR (n = 22)
Characteristics	SCT (n = 8)	No SCT (n = 8)	All other CR (n = 22)
Median age in years (range)	48.5 (17-61)	59.5 (14-76)	50.0 (17-74)
Female, n (%)	4 (50)	0	13 (59)
ECOG performance status, n (%)
Grade 0	2 (25)	2 (25)	11 (50)
Grade 1	6 (75)	6 (75)	11 (50)
ALK status, n (%)
Positive	4 (50)	1 (13)	5 (23)
Negative	4 (50)	7 (88)	17 (77)
Disease status relative to most recent prior therapy, n (%)*
Relapsed	5 (63)	6 (75)	11 (50)
Refractory	3 (38)	2 (25)	11 (50)
Primary refractory disease, n (%)†	4 (50)	3 (38)	16 (73)
Stage at initial diagnosis, n (%)
I/II	3 (38)	2 (25)	12 (55)
III/IV	4 (51)	2 (25)	10 (46)
Unknown	1 (13)	4 (50)	0
Median time in months from initial diagnosis to first dose (range)	21.7 (6.2-103.5)	21.83 (7.2-113.2)	19.55 (186.5)
Median time in months from most recent relapse to first dose (range)‡	1.2 (0.5-2.5)	1.6 (0.4-2.9)	2.1 (0.7-2.8)
Baseline B symptoms, n (%)§	4 (50)	1 (13)	6 (27)
Fever	3 (38)	0	3 (14)
Night sweats	2 (25)	1 (13)	5 (23)
Median baseline SPD of dominant nodes or nodal masses per investigator (cm², range)\|\|	15.7 (4.5-76.8)	12.1 (3.2, 47.8)	11.9 (2.0, 51.3)
Baseline bone marrow involvement, n (%)	0	0	2 (9)

Characteristics	CR patients in remission at EOS (n = 16)		All other CR (n = 22)
Characteristics	SCT (n = 8)	No SCT (n = 8)	All other CR (n = 22)
Median age in years (range)	48.5 (17-61)	59.5 (14-76)	50.0 (17-74)
Female, n (%)	4 (50)	0	13 (59)
ECOG performance status, n (%)
Grade 0	2 (25)	2 (25)	11 (50)
Grade 1	6 (75)	6 (75)	11 (50)
ALK status, n (%)
Positive	4 (50)	1 (13)	5 (23)
Negative	4 (50)	7 (88)	17 (77)
Disease status relative to most recent prior therapy, n (%)*
Relapsed	5 (63)	6 (75)	11 (50)
Refractory	3 (38)	2 (25)	11 (50)
Primary refractory disease, n (%)†	4 (50)	3 (38)	16 (73)
Stage at initial diagnosis, n (%)
I/II	3 (38)	2 (25)	12 (55)
III/IV	4 (51)	2 (25)	10 (46)
Unknown	1 (13)	4 (50)	0
Median time in months from initial diagnosis to first dose (range)	21.7 (6.2-103.5)	21.83 (7.2-113.2)	19.55 (186.5)
Median time in months from most recent relapse to first dose (range)‡	1.2 (0.5-2.5)	1.6 (0.4-2.9)	2.1 (0.7-2.8)
Baseline B symptoms, n (%)§	4 (50)	1 (13)	6 (27)
Fever	3 (38)	0	3 (14)
Night sweats	2 (25)	1 (13)	5 (23)
Median baseline SPD of dominant nodes or nodal masses per investigator (cm², range)\|\|	15.7 (4.5-76.8)	12.1 (3.2, 47.8)	11.9 (2.0, 51.3)
Baseline bone marrow involvement, n (%)	0	0	2 (9)

The categories of CR in remission at end of study include patients with a best response of CR without new treatment and free of known PD per investigator or death due to disease.

Relapse = best response of CR if a patient only had 1 prior therapy, or best response of CR or PR to most recent prior therapy if a patient had more than 1 prior therapy; refractory = best response of PR, SD, or PD if a patient had only 1 prior therapy, or best response of SD or PD to most recent prior therapy if a patient had more than 1 prior therapy.

†

No CR, or relapse within 3 months of frontline therapy.

‡

For those with relapsed disease status to most recent prior therapy.

B symptoms present at the time of cycle 1, day 1.

SPD of up to 6 of the largest dominant nodes or nodal masses.

Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only